Skip to main content
Top
Published in: Diabetologia 2/2008

01-02-2008 | Review

The mechanisms of alloxan- and streptozotocin-induced diabetes

Author: S. Lenzen

Published in: Diabetologia | Issue 2/2008

Login to get access

Abstract

Alloxan and streptozotocin are toxic glucose analogues that preferentially accumulate in pancreatic beta cells via the GLUT2 glucose transporter. In the presence of intracellular thiols, especially glutathione, alloxan generates reactive oxygen species (ROS) in a cyclic redox reaction with its reduction product, dialuric acid. Autoxidation of dialuric acid generates superoxide radicals, hydrogen peroxide and, in a final iron-catalysed reaction step, hydroxyl radicals. These hydroxyl radicals are ultimately responsible for the death of the beta cells, which have a particularly low antioxidative defence capacity, and the ensuing state of insulin-dependent ‘alloxan diabetes’. As a thiol reagent, alloxan also selectively inhibits glucose-induced insulin secretion through its ability to inhibit the beta cell glucose sensor glucokinase. Following its uptake into the beta cells, streptozotocin is split into its glucose and methylnitrosourea moiety. Owing to its alkylating properties, the latter modifies biological macromolecules, fragments DNA and destroys the beta cells, causing a state of insulin-dependent diabetes. The targeting of mitochondrial DNA, thereby impairing the signalling function of beta cell mitochondrial metabolism, also explains how streptozotocin is able to inhibit glucose-induced insulin secretion.
Literature
1.
go back to reference Wöhler F, Liebig J (1838) Untersuchungen über die Natur der Harnsäure. [Investigations on the nature of uric acid]. Ann Pharm 26:241–340 (article in German)CrossRef Wöhler F, Liebig J (1838) Untersuchungen über die Natur der Harnsäure. [Investigations on the nature of uric acid]. Ann Pharm 26:241–340 (article in German)CrossRef
2.
3.
go back to reference Lenzen S, Tiedge M, Jörns A, Munday R (1996) Alloxan derivatives as a tool for the elucidation of the mechanism of the diabetogenic action of alloxan. In: Shafrir E (ed) Lessons from animal diabetes. Birkhäuser, Boston, pp 113–122 Lenzen S, Tiedge M, Jörns A, Munday R (1996) Alloxan derivatives as a tool for the elucidation of the mechanism of the diabetogenic action of alloxan. In: Shafrir E (ed) Lessons from animal diabetes. Birkhäuser, Boston, pp 113–122
4.
go back to reference Dunn JS, McLetchie NGB (1943) Experimental alloxan diabetes in the rat. Lancet 245:384–387 Dunn JS, McLetchie NGB (1943) Experimental alloxan diabetes in the rat. Lancet 245:384–387
5.
go back to reference Dunn JS, Sheehan HL, McLetchie NGB (1943) Necrosis of islets of Langerhans produced experimentally. Lancet 244:484–487 Dunn JS, Sheehan HL, McLetchie NGB (1943) Necrosis of islets of Langerhans produced experimentally. Lancet 244:484–487
6.
go back to reference Jörns A, Munday R, Tiedge M, Lenzen S (1997) Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro. J Endocrinol 155:283–293PubMedCrossRef Jörns A, Munday R, Tiedge M, Lenzen S (1997) Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro. J Endocrinol 155:283–293PubMedCrossRef
7.
go back to reference Peschke E, Ebelt H, Brömme HJ, Peschke D (2000) ‘Classical’ and ‘new’ diabetogens—comparison of their effects on isolated rat pancreatic islets in vitro. Cell Mol Life Sci 57:158–164PubMedCrossRef Peschke E, Ebelt H, Brömme HJ, Peschke D (2000) ‘Classical’ and ‘new’ diabetogens—comparison of their effects on isolated rat pancreatic islets in vitro. Cell Mol Life Sci 57:158–164PubMedCrossRef
8.
go back to reference Goldner MG, Gomori G (1943) Alloxan diabetes in the dog. Endocrinology 33:297–308 Goldner MG, Gomori G (1943) Alloxan diabetes in the dog. Endocrinology 33:297–308
9.
10.
go back to reference Bailey CC, Bailey OT, Leech RS (1946) Diabetes mellitus in rabbits injected with dialuric acid. Proc Soc Exp Biol Med 63:502–505 Bailey CC, Bailey OT, Leech RS (1946) Diabetes mellitus in rabbits injected with dialuric acid. Proc Soc Exp Biol Med 63:502–505
11.
go back to reference Brückmann G, Wertheimer E (1947) Alloxan studies: the action of alloxan homologues and related compounds. J Biol Chem 168:241–256 Brückmann G, Wertheimer E (1947) Alloxan studies: the action of alloxan homologues and related compounds. J Biol Chem 168:241–256
12.
13.
go back to reference Schein PS, Cooney DA, Vernon ML (1967) The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 27:2324–2332PubMed Schein PS, Cooney DA, Vernon ML (1967) The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 27:2324–2332PubMed
14.
go back to reference Schein PS, O’Connell MJ, Blom J et al (1974) Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 34:993–1000PubMedCrossRef Schein PS, O’Connell MJ, Blom J et al (1974) Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 34:993–1000PubMedCrossRef
15.
go back to reference Rakieten N, Rakieten ML, Nadkarni MV (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91–98 Rakieten N, Rakieten ML, Nadkarni MV (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91–98
16.
go back to reference Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP (1967) Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16:51–56PubMed Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP (1967) Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16:51–56PubMed
17.
go back to reference Rerup CC (1970) Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22:485–518PubMed Rerup CC (1970) Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22:485–518PubMed
18.
go back to reference Cooperstein SJ, Watkins D (1981) Action of toxic drugs on islet cells. In: Cooperstein SJ, Watkins D (eds) The islet of Langerhans. Academic, New York, pp 387–425 Cooperstein SJ, Watkins D (1981) Action of toxic drugs on islet cells. In: Cooperstein SJ, Watkins D (eds) The islet of Langerhans. Academic, New York, pp 387–425
19.
go back to reference Weiss RB (1982) Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 66:427–438PubMed Weiss RB (1982) Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 66:427–438PubMed
20.
go back to reference Preston AM (1985) Modification of streptozotocin-induced diabetes by protective agents. Nutr Res 5:435–446CrossRef Preston AM (1985) Modification of streptozotocin-induced diabetes by protective agents. Nutr Res 5:435–446CrossRef
21.
go back to reference Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537–546PubMed Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537–546PubMed
22.
go back to reference Lenzen S (2007) Alloxan and streptozotocin diabetes. In: Peschke E (ed) Endokrinologie III Vorträge im Rahmen des Projektes ‘Zeitstrukturen endokriner Systeme’. [Endocrinology III lectures within the ‘time structures of endocrine systems’ project framework]. Abhandlung der Sächs. Akad. Wiss., Math-naturwiss Klasse, Verlag der Sächsischen Akademie der Wissenschaften, Leipzig, commissioned by S. Hirzel Verlag, Stuttgart/Leipzig, pp 119–138 Lenzen S (2007) Alloxan and streptozotocin diabetes. In: Peschke E (ed) Endokrinologie III Vorträge im Rahmen des Projektes ‘Zeitstrukturen endokriner Systeme’. [Endocrinology III lectures within the ‘time structures of endocrine systems’ project framework]. Abhandlung der Sächs. Akad. Wiss., Math-naturwiss Klasse, Verlag der Sächsischen Akademie der Wissenschaften, Leipzig, commissioned by S. Hirzel Verlag, Stuttgart/Leipzig, pp 119–138
23.
go back to reference Lenzen S, Munday R (1991) Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 42:1385–1391PubMedCrossRef Lenzen S, Munday R (1991) Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 42:1385–1391PubMedCrossRef
24.
go back to reference Weaver DC, Barry CD, McDaniel ML, Marshall GR, Lacy PE (1979) Molecular requirements for recognition at glucoreceptor for insulin release. Mol Pharmacol 16:361–368PubMed Weaver DC, Barry CD, McDaniel ML, Marshall GR, Lacy PE (1979) Molecular requirements for recognition at glucoreceptor for insulin release. Mol Pharmacol 16:361–368PubMed
25.
go back to reference Gorus FK, Malaisse WJ, Pipeleers DG (1982) Selective uptake of alloxan by pancreatic B-cells. Biochem J 208:513–515PubMed Gorus FK, Malaisse WJ, Pipeleers DG (1982) Selective uptake of alloxan by pancreatic B-cells. Biochem J 208:513–515PubMed
26.
go back to reference Weaver DC, McDaniel ML, Lacy PE (1978) Alloxan uptake by isolated rat islets of Langerhans. Endocrinology 102:1847–1855PubMed Weaver DC, McDaniel ML, Lacy PE (1978) Alloxan uptake by isolated rat islets of Langerhans. Endocrinology 102:1847–1855PubMed
27.
go back to reference Elsner M, Tiedge M, Guldbakke B, Munday R, Lenzen S (2002) Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia 45:1542–1549PubMedCrossRef Elsner M, Tiedge M, Guldbakke B, Munday R, Lenzen S (2002) Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia 45:1542–1549PubMedCrossRef
28.
go back to reference Hammarström L, Hellman B, Ullberg S (1967) On the accumulation of alloxan in the pancreatic beta-cells. Diabetologia 3:340–344PubMedCrossRef Hammarström L, Hellman B, Ullberg S (1967) On the accumulation of alloxan in the pancreatic beta-cells. Diabetologia 3:340–344PubMedCrossRef
29.
go back to reference Boquist L, Nelson L, Lorentzon R (1983) Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. Endocrinology 113:943–948PubMed Boquist L, Nelson L, Lorentzon R (1983) Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. Endocrinology 113:943–948PubMed
30.
go back to reference Malaisse WJ, Doherty M, Ladriere L, Malaisse-Lagae F (2001) Pancreatic uptake of [2-14C]alloxan. Int J Mol Med 7:311–315PubMed Malaisse WJ, Doherty M, Ladriere L, Malaisse-Lagae F (2001) Pancreatic uptake of [2-14C]alloxan. Int J Mol Med 7:311–315PubMed
31.
go back to reference Bloch KO, Zemel R, Bloch OV, Grief H, Vardi P (2000) Streptozotocin and alloxan-based selection improves toxin resistance of insulin-producing RINm cells. Int J Exp Diabetes Res 1:211–219PubMedCrossRef Bloch KO, Zemel R, Bloch OV, Grief H, Vardi P (2000) Streptozotocin and alloxan-based selection improves toxin resistance of insulin-producing RINm cells. Int J Exp Diabetes Res 1:211–219PubMedCrossRef
32.
go back to reference Patterson JW, Lazarow A, Levey S (1949) Alloxan and dialuric acid: their stabilities and ultraviolet absorption spectra. J Biol Chem 177:187–196PubMed Patterson JW, Lazarow A, Levey S (1949) Alloxan and dialuric acid: their stabilities and ultraviolet absorption spectra. J Biol Chem 177:187–196PubMed
33.
go back to reference Gomori G, Goldner MG (1945) Acute nature of alloxan damage. Proc Soc Exp Biol (NY) 58:232–233 Gomori G, Goldner MG (1945) Acute nature of alloxan damage. Proc Soc Exp Biol (NY) 58:232–233
34.
go back to reference Bailey CC, Collins-Williams J, Le Compte PM (1950) Effect of alloxan in rabbits with temporary occlusion of the arteries to the pancreas. Proc Soc Exp Biol 71:580–583 Bailey CC, Collins-Williams J, Le Compte PM (1950) Effect of alloxan in rabbits with temporary occlusion of the arteries to the pancreas. Proc Soc Exp Biol 71:580–583
35.
go back to reference Hellman B, Diderholm H (1955) The diabetogenic effect of alloxan after elimination of extra-pancreatic factors. Acta Endocrinol (Copenh) 20:81–87 Hellman B, Diderholm H (1955) The diabetogenic effect of alloxan after elimination of extra-pancreatic factors. Acta Endocrinol (Copenh) 20:81–87
36.
go back to reference Munday R, Ludwig K, Lenzen S (1993) The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. J Endocrinol 139:153–163PubMed Munday R, Ludwig K, Lenzen S (1993) The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. J Endocrinol 139:153–163PubMed
37.
go back to reference Hara H, Miwa I, Okuda J (1986) Inhibition of rat liver glucokinase by alloxan and ninhydrin. Chem Pharm Bull (Tokyo) 34:4731–4737 Hara H, Miwa I, Okuda J (1986) Inhibition of rat liver glucokinase by alloxan and ninhydrin. Chem Pharm Bull (Tokyo) 34:4731–4737
38.
go back to reference Meglasson MD, Burch PT, Berner DK, Najafi H, Matschinsky FM (1986) Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cell. Diabetes 35:1163–1173PubMedCrossRef Meglasson MD, Burch PT, Berner DK, Najafi H, Matschinsky FM (1986) Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cell. Diabetes 35:1163–1173PubMedCrossRef
39.
go back to reference Lenzen S, Tiedge M, Panten U (1987) Glucokinase in pancreatic B-cells and its inhibition by alloxan. Acta Endocrinol (Copenh) 115:21–29 Lenzen S, Tiedge M, Panten U (1987) Glucokinase in pancreatic B-cells and its inhibition by alloxan. Acta Endocrinol (Copenh) 115:21–29
40.
go back to reference Tiedge M, Richter T, Lenzen S (2000) Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase. Arch Biochem Biophys 375:251–260PubMedCrossRef Tiedge M, Richter T, Lenzen S (2000) Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase. Arch Biochem Biophys 375:251–260PubMedCrossRef
41.
go back to reference Konrad RJ, Kudlow JE (2002) The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med 10:535–539PubMed Konrad RJ, Kudlow JE (2002) The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med 10:535–539PubMed
42.
go back to reference Gunnarsson R, Hellerström C (1973) Acute effects of alloxan on the metabolism and insulin secretion of the pancreatic B-cell. Horm Metab Res 5:404–409PubMedCrossRef Gunnarsson R, Hellerström C (1973) Acute effects of alloxan on the metabolism and insulin secretion of the pancreatic B-cell. Horm Metab Res 5:404–409PubMedCrossRef
43.
go back to reference Weaver DC, McDaniel ML, Naber SP, Barry CD, Lacy PE (1978) Alloxan stimulation and inhibition of insulin release from isolated rat islets of Langerhans. Diabetes 27:1205–1214PubMedCrossRef Weaver DC, McDaniel ML, Naber SP, Barry CD, Lacy PE (1978) Alloxan stimulation and inhibition of insulin release from isolated rat islets of Langerhans. Diabetes 27:1205–1214PubMedCrossRef
44.
45.
go back to reference Ishibashi F, Onari K, Sato T, Kawate R (1978) Studies on the mechanism of alloxan inhibition of glucose-induced insulin release. Hiroshima J Med Sci 27:211–219PubMed Ishibashi F, Onari K, Sato T, Kawate R (1978) Studies on the mechanism of alloxan inhibition of glucose-induced insulin release. Hiroshima J Med Sci 27:211–219PubMed
46.
go back to reference Miwa I, Hara H, Okuda J (1986) Parallel inhibition of islet glucokinase and glucose-stimulated insulin secretion by either alloxan or ninhydrin. J Clin Biochem Nutr 1:237–245 Miwa I, Hara H, Okuda J (1986) Parallel inhibition of islet glucokinase and glucose-stimulated insulin secretion by either alloxan or ninhydrin. J Clin Biochem Nutr 1:237–245
47.
go back to reference Jain K, Logothetopoulos J (1976) Proinsulin biosynthesis by pancreatic islets of the rat and the study of alloxan cytotoxicity in vitro. Biochim Biophys Acta 435:145–151PubMed Jain K, Logothetopoulos J (1976) Proinsulin biosynthesis by pancreatic islets of the rat and the study of alloxan cytotoxicity in vitro. Biochim Biophys Acta 435:145–151PubMed
48.
go back to reference Niki A, Niki H, Miwa I, Lin BJ (1976) Interaction of alloxan and anomers of d-glucose on glucose-induced insulin secretion and biosynthesis in vitro. Diabetes 25:574–579PubMedCrossRef Niki A, Niki H, Miwa I, Lin BJ (1976) Interaction of alloxan and anomers of d-glucose on glucose-induced insulin secretion and biosynthesis in vitro. Diabetes 25:574–579PubMedCrossRef
49.
go back to reference Lenzen S, Brand FH, Panten U (1988) Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition. Br J Pharmacol 95:851–859PubMed Lenzen S, Brand FH, Panten U (1988) Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition. Br J Pharmacol 95:851–859PubMed
50.
go back to reference Borg LA (1981) Effects of alloxan on the islets of Langerhans: inhibition of leucine metabolism and insulin secretion. Biochim Biophys Acta 677:257–262PubMed Borg LA (1981) Effects of alloxan on the islets of Langerhans: inhibition of leucine metabolism and insulin secretion. Biochim Biophys Acta 677:257–262PubMed
51.
go back to reference Lenzen S, Freytag S, Panten U (1988) Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. Mol Pharmacol 34:395–400PubMed Lenzen S, Freytag S, Panten U (1988) Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. Mol Pharmacol 34:395–400PubMed
52.
go back to reference Lenzen S, Mirzaie-Petri M (1991) Inhibition of glucokinase and hexokinase from pancreatic B-cells and liver by alloxan, alloxantin, dialuric acid, and t-butylhydroperoxide. Biomed Res 12:297–307 Lenzen S, Mirzaie-Petri M (1991) Inhibition of glucokinase and hexokinase from pancreatic B-cells and liver by alloxan, alloxantin, dialuric acid, and t-butylhydroperoxide. Biomed Res 12:297–307
53.
go back to reference Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447–2452PubMed Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447–2452PubMed
54.
go back to reference Munday R (1988) Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of ‘active oxygen’ species. Biochem Pharmacol 37:409–413PubMedCrossRef Munday R (1988) Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of ‘active oxygen’ species. Biochem Pharmacol 37:409–413PubMedCrossRef
55.
go back to reference Winterbourn CC, Cowden WB, Sutton HC (1989) Auto-oxidation of dialuric acid, divicine and isouramil. Superoxide dependent and independent mechanisms. Biochem Pharmacol 38:611–618PubMedCrossRef Winterbourn CC, Cowden WB, Sutton HC (1989) Auto-oxidation of dialuric acid, divicine and isouramil. Superoxide dependent and independent mechanisms. Biochem Pharmacol 38:611–618PubMedCrossRef
56.
go back to reference Winterbourn CC, Munday R (1989) Glutathione-mediated redox cycling of alloxan. Mechanisms of superoxide dismutase inhibition and of metal-catalyzed \( OH^{ \bullet } \) formation. Biochem Pharmacol 38:271–277PubMedCrossRef Winterbourn CC, Munday R (1989) Glutathione-mediated redox cycling of alloxan. Mechanisms of superoxide dismutase inhibition and of metal-catalyzed \( OH^{ \bullet } \) formation. Biochem Pharmacol 38:271–277PubMedCrossRef
58.
go back to reference Brömme HJ, Mörke W, Peschke D, Ebelt H (2000) Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 29:201–208PubMedCrossRef Brömme HJ, Mörke W, Peschke D, Ebelt H (2000) Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 29:201–208PubMedCrossRef
59.
go back to reference Elsner M, Gurgul-Convey E, Lenzen S (2007) Relation between triketone structure, generation of reactive oxygen species and selective toxicity of the diabetogenic agent alloxan. Antioxid Redox Signal (in press) Elsner M, Gurgul-Convey E, Lenzen S (2007) Relation between triketone structure, generation of reactive oxygen species and selective toxicity of the diabetogenic agent alloxan. Antioxid Redox Signal (in press)
60.
go back to reference Elsner M, Gurgul-Convey E, Lenzen S (2006) Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. Free Radic Biol Med 41:825–834PubMedCrossRef Elsner M, Gurgul-Convey E, Lenzen S (2006) Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. Free Radic Biol Med 41:825–834PubMedCrossRef
61.
go back to reference Lenzen S, Mirzaie-Petri M (1992) Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose. Naunyn Schmiedebergs Arch Pharmacol 346:532–536PubMedCrossRef Lenzen S, Mirzaie-Petri M (1992) Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose. Naunyn Schmiedebergs Arch Pharmacol 346:532–536PubMedCrossRef
62.
go back to reference Sakurai K, Miura T (1989) Generation of free radicals by alloxan in the presence of bovine serum albumin: a role of protein sulfhydryl groups in alloxan cytotoxicity. Biochem Int 19:405–412PubMed Sakurai K, Miura T (1989) Generation of free radicals by alloxan in the presence of bovine serum albumin: a role of protein sulfhydryl groups in alloxan cytotoxicity. Biochem Int 19:405–412PubMed
63.
go back to reference Brömme HJ, Mörke W, Weinandy R, Peschke D, Peschke E (2002) Formation of compound 305 requires the simultaneous generation of both alloxan and GSH radicals. Horm Metab Res 34:62–66PubMed Brömme HJ, Mörke W, Weinandy R, Peschke D, Peschke E (2002) Formation of compound 305 requires the simultaneous generation of both alloxan and GSH radicals. Horm Metab Res 34:62–66PubMed
64.
go back to reference Lazarow A, Patterson JW, Levey S (1948) The mechanism of cysteine and glutathione protection against alloxan diabetes. Science 108:308–309PubMedCrossRef Lazarow A, Patterson JW, Levey S (1948) The mechanism of cysteine and glutathione protection against alloxan diabetes. Science 108:308–309PubMedCrossRef
65.
go back to reference Sen PB, Bhattacharya G (1952) Reversal of the diabetogenic action of alloxan by sulfhydryl compounds. Science 115:41–43PubMedCrossRef Sen PB, Bhattacharya G (1952) Reversal of the diabetogenic action of alloxan by sulfhydryl compounds. Science 115:41–43PubMedCrossRef
66.
go back to reference Grankvist K, Marklund S, Sehlin J, Taljedal IB (1979) Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. Biochem J 182:17–25PubMed Grankvist K, Marklund S, Sehlin J, Taljedal IB (1979) Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. Biochem J 182:17–25PubMed
67.
go back to reference Tiedge M, Lortz S, Drinkgern J, Lenzen S (1997) Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733–1742PubMedCrossRef Tiedge M, Lortz S, Drinkgern J, Lenzen S (1997) Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733–1742PubMedCrossRef
68.
go back to reference Tibaldi J, Benjamin J, Cabbat FS, Heikkila RE (1979) Protection against alloxan-induced diabetes by various urea derivatives: relationship between protective effects and reactivity with the hydroxyl radical. J Pharmacol Exp Ther 211:415–418PubMed Tibaldi J, Benjamin J, Cabbat FS, Heikkila RE (1979) Protection against alloxan-induced diabetes by various urea derivatives: relationship between protective effects and reactivity with the hydroxyl radical. J Pharmacol Exp Ther 211:415–418PubMed
69.
go back to reference Fischer LJ, Harman AW (1982) Oxygen free radicals and the diabetogenic action of alloxan. In: Autor AP (ed) Pathology of oxygen. Academic, New York, pp 261–275 Fischer LJ, Harman AW (1982) Oxygen free radicals and the diabetogenic action of alloxan. In: Autor AP (ed) Pathology of oxygen. Academic, New York, pp 261–275
70.
go back to reference Jörns A, Tiedge M, Lenzen S, Munday R (1999) Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro. Free Radic Biol Med 26:1300–1304PubMedCrossRef Jörns A, Tiedge M, Lenzen S, Munday R (1999) Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro. Free Radic Biol Med 26:1300–1304PubMedCrossRef
71.
go back to reference Grankvist K, Marklund S, Täljedal IB (1979) Influence of trace metals on alloxan cytotoxicity in pancreatic islets. FEBS Lett 105:15–18PubMedCrossRef Grankvist K, Marklund S, Täljedal IB (1979) Influence of trace metals on alloxan cytotoxicity in pancreatic islets. FEBS Lett 105:15–18PubMedCrossRef
72.
go back to reference Heikkila RE, Cabbat FS (1982) The prevention of alloxan-induced diabetes in mice by the iron-chelator detapac: suggestion of a role for iron in the cytotoxic process. Experientia 38:378–379PubMedCrossRef Heikkila RE, Cabbat FS (1982) The prevention of alloxan-induced diabetes in mice by the iron-chelator detapac: suggestion of a role for iron in the cytotoxic process. Experientia 38:378–379PubMedCrossRef
73.
go back to reference Heikkila RE, Winston B, Cohen G (1976) Alloxan-induced diabetes-evidence for hydroxyl radical as a cytotoxic intermediate. Biochem Pharmacol 25:1085–1092PubMedCrossRef Heikkila RE, Winston B, Cohen G (1976) Alloxan-induced diabetes-evidence for hydroxyl radical as a cytotoxic intermediate. Biochem Pharmacol 25:1085–1092PubMedCrossRef
74.
go back to reference Tjälve H, Wilander E, Johansson EB (1976) Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. J Endocrinol 69:455–456PubMed Tjälve H, Wilander E, Johansson EB (1976) Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. J Endocrinol 69:455–456PubMed
75.
go back to reference Karunanayake EH, Baker JR, Christian RA, Hearse DJ, Mellows G (1976) Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat. Diabetologia 12:123–128PubMedCrossRef Karunanayake EH, Baker JR, Christian RA, Hearse DJ, Mellows G (1976) Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat. Diabetologia 12:123–128PubMedCrossRef
76.
go back to reference Ledoux SP, Wilson GL (1984) Effects of streptozotocin on a clonal isolate of rat insulinoma cells. Biochim Biophys Acta 804:387–392PubMedCrossRef Ledoux SP, Wilson GL (1984) Effects of streptozotocin on a clonal isolate of rat insulinoma cells. Biochim Biophys Acta 804:387–392PubMedCrossRef
77.
go back to reference Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S (2000) Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43:1528–1533PubMedCrossRef Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S (2000) Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43:1528–1533PubMedCrossRef
78.
go back to reference Schnedl WJ, Ferber S, Johnson JH, Newgard CB (1994) STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43:1326–1333PubMedCrossRef Schnedl WJ, Ferber S, Johnson JH, Newgard CB (1994) STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43:1326–1333PubMedCrossRef
79.
go back to reference Ledoux SP, Woodley SE, Patton NJ, Wilson GL (1986) Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. Diabetes 35:866–872PubMedCrossRef Ledoux SP, Woodley SE, Patton NJ, Wilson GL (1986) Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. Diabetes 35:866–872PubMedCrossRef
80.
go back to reference Wilson GL, Hartig PC, Patton NJ, LeDoux SP (1988) Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly(ADP-ribose) synthetase and cellular distribution. Diabetes 37:213–216PubMedCrossRef Wilson GL, Hartig PC, Patton NJ, LeDoux SP (1988) Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly(ADP-ribose) synthetase and cellular distribution. Diabetes 37:213–216PubMedCrossRef
81.
go back to reference Bennett RA, Pegg AE (1981) Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res 41:2786–2790PubMed Bennett RA, Pegg AE (1981) Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res 41:2786–2790PubMed
82.
go back to reference Uchigata Y, Yamamoto H, Kawamura A, Okamoto H (1982) Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem 257:6084–6088PubMed Uchigata Y, Yamamoto H, Kawamura A, Okamoto H (1982) Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem 257:6084–6088PubMed
83.
go back to reference Murata M, Takahashi A, Saito I, Kawanishi S (1999) Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 57:881–887PubMedCrossRef Murata M, Takahashi A, Saito I, Kawanishi S (1999) Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 57:881–887PubMedCrossRef
84.
go back to reference Pieper AA, Verma A, Zhang J, Snyder SH (1999) Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20:171–181PubMedCrossRef Pieper AA, Verma A, Zhang J, Snyder SH (1999) Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20:171–181PubMedCrossRef
85.
go back to reference Yamamoto H, Uchigata Y, Okamoto H (1981) Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294:284–286PubMedCrossRef Yamamoto H, Uchigata Y, Okamoto H (1981) Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294:284–286PubMedCrossRef
86.
go back to reference Schein PS, Loftus S (1968) Streptozotocin: depression of mouse liver pyridine nucleotides. Cancer Res 28:1501–1506PubMed Schein PS, Loftus S (1968) Streptozotocin: depression of mouse liver pyridine nucleotides. Cancer Res 28:1501–1506PubMed
87.
go back to reference Sandler S, Swenne I (1983) Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia 25:444–447PubMedCrossRef Sandler S, Swenne I (1983) Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia 25:444–447PubMedCrossRef
88.
go back to reference Pieper AA, Brat DJ, Krug DK et al (1999) Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:3059–3064PubMedCrossRef Pieper AA, Brat DJ, Krug DK et al (1999) Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:3059–3064PubMedCrossRef
89.
go back to reference Burkart V, Wang ZQ, Radons J et al (1999) Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5:314–319PubMedCrossRef Burkart V, Wang ZQ, Radons J et al (1999) Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5:314–319PubMedCrossRef
90.
go back to reference Masutani M, Suzuki H, Kamada N et al (1999) Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:2301–2304PubMedCrossRef Masutani M, Suzuki H, Kamada N et al (1999) Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:2301–2304PubMedCrossRef
91.
go back to reference Delaney CA, Dunger A, Di Matteo M, Cunningham JM, Green MH, Green IC (1995) Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. Biochem Pharmacol 50:2015–2020PubMedCrossRef Delaney CA, Dunger A, Di Matteo M, Cunningham JM, Green MH, Green IC (1995) Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. Biochem Pharmacol 50:2015–2020PubMedCrossRef
92.
go back to reference Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML (1993) Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun 197:1458–1464PubMedCrossRef Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML (1993) Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun 197:1458–1464PubMedCrossRef
93.
go back to reference Nukatsuka M, Yoshimura Y, Nishida M, Kawada J (1990) Allopurinol protects pancreatic beta cells from the cytotoxic effect of streptozotocin: in vitro study. J Pharmacobiodyn 13:259–262PubMed Nukatsuka M, Yoshimura Y, Nishida M, Kawada J (1990) Allopurinol protects pancreatic beta cells from the cytotoxic effect of streptozotocin: in vitro study. J Pharmacobiodyn 13:259–262PubMed
94.
go back to reference Strandell E, Eizirik DL, Korsgren O, Sandler S (1988) Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 59:83–91PubMedCrossRef Strandell E, Eizirik DL, Korsgren O, Sandler S (1988) Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 59:83–91PubMedCrossRef
95.
go back to reference Bedoya FJ, Solano F, Lucas M (1996) N-Monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Experientia 52:344–347PubMedCrossRef Bedoya FJ, Solano F, Lucas M (1996) N-Monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Experientia 52:344–347PubMedCrossRef
96.
go back to reference Wang Z, Gleichmann H (1998) GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47:50–56PubMedCrossRef Wang Z, Gleichmann H (1998) GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47:50–56PubMedCrossRef
97.
go back to reference Eizirik DL, Sandler S, Sener A, Malaisse WJ (1988) Defective catabolism of d-glucose and l-glutamine in mouse pancreatic islets maintained in culture after streptozotocin exposure. Endocrinology 123:1001–1007PubMed Eizirik DL, Sandler S, Sener A, Malaisse WJ (1988) Defective catabolism of d-glucose and l-glutamine in mouse pancreatic islets maintained in culture after streptozotocin exposure. Endocrinology 123:1001–1007PubMed
98.
go back to reference Rasschaert J, Eizirik DL, Malaisse WJ (1992) Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. Endocrinology 130:3522–3528PubMedCrossRef Rasschaert J, Eizirik DL, Malaisse WJ (1992) Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. Endocrinology 130:3522–3528PubMedCrossRef
99.
go back to reference Eizirik DL, Sandler S, Ahnström G, Welsh M (1991) Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. Biochem Pharmacol 42:2275–2282PubMedCrossRef Eizirik DL, Sandler S, Ahnström G, Welsh M (1991) Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. Biochem Pharmacol 42:2275–2282PubMedCrossRef
100.
go back to reference Strandell E, Eizirik DL, Sandler S (1989) Survival and B-cell function of mouse pancreatic islets maintained in culture after concomitant exposure to streptozotocin and nicotinamide. Exp Clin Endocrinol 93:219–224PubMedCrossRef Strandell E, Eizirik DL, Sandler S (1989) Survival and B-cell function of mouse pancreatic islets maintained in culture after concomitant exposure to streptozotocin and nicotinamide. Exp Clin Endocrinol 93:219–224PubMedCrossRef
101.
go back to reference Elsner M, Tiedge M, Lenzen S (2003) Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan. Diabetologia 46:1713–1714PubMedCrossRef Elsner M, Tiedge M, Lenzen S (2003) Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan. Diabetologia 46:1713–1714PubMedCrossRef
Metadata
Title
The mechanisms of alloxan- and streptozotocin-induced diabetes
Author
S. Lenzen
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0886-7

Other articles of this Issue 2/2008

Diabetologia 2/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.